Insights into Renal Cell Carcinoma (RCC) 2020

Current treatment practice regarding therapy of advanced renal cell carcinoma (RCC), recently introduced and upcoming agents

Southern California and Arizona – December 3, 2020

Faculty Chair

Sumanta Kumar Pal, MD

City of Hope Comprehensive Cancer Center, Duarte, CA

Example Report

Start discovering the insights

View Report


  • A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of advanced RCC was held on December 3, 2020, in a virtual setting
  • Disease state and data presentations were developed by Sumanta Kumar Pal, MD, a medical expert from City of Hope Comprehensive Cancer Center, Duarte, California
  • The group of advisors comprised 12 community oncologists from practices in the southwest United States
  • Insights on the following therapies were obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs


  • Data collection was accomplished through use of audience response system (ARS) questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from practices across Southern California and Arizona

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.